Rheumatoid Arthritis vs Osteoarthritis: Key Differences

The 1987 ACR criteria remain widely used for rheumatoid arthritis diagnosis, requiring evidence of inflammatory arthritis, involvement of at least one joint, and disease duration of at least 6 weeks. The 2010 EULAR/ACR criteria improve early disease detection by including joint involvement, serology, acute phase reactants, and functional impairment. Disease staging is based on radiographic changes: Stage 1 shows no radiographic changes, Stage 2 shows erosions and joint space narrowing, Stage 3 shows more severe erosions and deformity, and Stage 4 shows severe joint destruction and fusion.

ACR 1987 criteria require 4/7 criteria: morning stiffness >1 hour, arthritis in 3+ joint areas (at least one small hand joint), symmetric involvement, rheumatoid nodules, RF positivity, and radiographic changes. ACR 2010 uses a scoring system (0-10 points) based on joint involvement, serology, acute phase reactants, and duration, requiring ≥6 points. Radiographic staging follows van der Heijde modification: Stage 0 (normal), Stage 1 (periarticular osteopenia), Stage 2 (joint space narrowing), Stage 3 (erosions), Stage 4 (deformity/ankylosis). This staging guides treatment decisions and prognosis assessment.

The 2010 ACR/EULAR classification criteria enable early RA diagnosis before radiographic changes. Two requirements: (1) at least one joint with definite clinical signs of arthritis, (2) arthritis not better explained by another disease. Four domains are scored: joint distribution (0-5 points), serology (0-3 points), symptom duration (0-1 point), and acute phase reactants (0-1 point). Total score of 6 or more defines RA. This system allows prospective or retrospective classification and enables early intervention to prevent joint destruction.

The new Rheumatoid Arthritis classification criteria focus on four evaluations: (1) Joint involvement assessed by counting tender and swollen joints with assigned scores; (2) Duration of symptoms (more than six weeks of pain, stiffness, or swelling counts as one score); (3) Inflammation markers (high ESR or C-Reactive Protein adds to the score); (4) Serological markers (Rheumatoid Factor and Anti-CCP Antibodies add one or two points respectively). A total score of six or above meets the criteria for Rheumatoid Arthritis.

Radiographic examination is essential for confirming rheumatoid arthritis diagnosis, staging disease, and monitoring progression. The four radiographic stages are: Stage 1 - mild periarticular osteoporosis; Stage 2 - moderate osteoporosis with multiple lucencies, joint space narrowing, and single erosions; Stage 3 - moderate to severe osteoporosis with multiple erosions (>5); Stage 4 - severe osteoporosis with cysts, multiple erosions, deformities, subluxations, and bony ankylosis. Key radiographic features include periarticular osteoporosis, marginal erosions, irregular joint surfaces, joint space narrowing, microcysts, and complete bone destruction. The 2010 EULAR classification criteria use a point system: joint involvement (0-5 points), serology (0-3 points), acute phase reactants (0-2 points), and symptom duration (>6 weeks). A score of 6+ indicates probable rheumatoid arthritis. Comprehensive diagnosis requires clinical assessment of joint involvement and extra-articular manifestations, serological testing, laboratory evaluation, radiographic staging, and assessment of functional impairment.

For severe rheumatoid arthritis that has not responded to other treatments, doctors may recommend surgical procedures. Joint replacement (arthroplasty) may be recommended for joints that are difficult to replace. Joint fusion (arthodesis) may be recommended during which the joint is removed and the bones are fused together with bone graft. Another surgical procedure is synovectomy, during which the synovial membrane surrounding the joint is removed. In some cases, an arthritic joint may need to be replaced with an artificial joint.

When degenerative joint disease progresses to cause intractable pain and severe mobility limitations, total joint replacement (arthroplasty) becomes necessary. This procedure has become routine in both public and private hospitals, with modern implants and experienced surgeons. Revision joint replacement addresses cases where previous implants have loosened after 10-15 years. Minimally invasive techniques represent an emerging advancement, aiming to reduce tissue damage and potentially accelerate recovery. These surgical options restore function and quality of life for patients with end-stage joint disease.

Intra-articular corticosteroid injections provide effective pain relief for osteoarthritis, particularly in joints with significant inflammation. They should be limited to 3-4 injections per year due to potential cartilage damage and infection risk. Combination injections with local anesthetics (lidocaine) provide immediate pain relief while corticosteroids take effect. Local side effects include infection, post-injection flare, tendon rupture, and skin atrophy. Surgical options include arthroscopy for assessment and minor interventions, arthroplasty (joint replacement) for end-stage disease, and arthrodesis (joint fusion) when replacement is not feasible. The choice depends on joint involvement, patient age, activity level, and overall health.

Surgical options include osteotomy (bone cutting to change mechanical axis), arthrodesis (fusion), and joint replacement. Osteotomy is indicated for younger patients with limited joint damage. Arthrodesis eliminates movement and is reserved for infection or non-ambulatory patients. Joint replacement (arthroplasty) is the standard for end-stage disease, with partial or total options depending on patient factors. Patient selection is critical for successful outcomes.

Surgical interventions are reserved for patients with advanced disease who have failed conservative management. Joint replacement surgery (total knee arthroplasty) is the definitive treatment for end-stage osteoarthritis. Arthroscopic surgery and microfracture are no longer recommended based on evidence showing lack of long-term benefit. Intra-articular corticosteroid injections may be considered for patients with significant inflammatory component and joint effusion, but should be limited to no more than 3 per year to minimize potential adverse effects on cartilage.

Osteoarthritis must be differentiated from several other conditions: psoriatic arthritis (affects DIP joints but has characteristic skin/nail changes), gout (acute severe pain with tophi), and ankylosing spondylitis (inflammatory back pain in young adults). Misdiagnosis can occur when osteoarthritis is complicated by carpal tunnel syndrome, as inflammatory markers remain normal. Treatment with anti-inflammatory drugs for rheumatoid arthritis may not relieve symptoms if the underlying condition is osteoarthritis.

Pyrophosphate arthropathy must be differentiated from multiple conditions: (1) Rheumatoid arthritis - differentiated by seronegativity for ACPA/anti-CCP and involvement of distal interphalangeal joints; (2) Psoriatic arthritis - differentiated by absence of psoriasis and classic dactylitis; (3) Ankylosing spondylitis - differentiated by lack of sacroiliitis and HLA-B27 negativity; (4) Gout - differentiated by less common podagra and female predominance; (5) Systemic lupus erythematosus - differentiated by absence of salivary gland enlargement and characteristic immunological markers; (6) Forestier's disease (DISH) - differentiated by absence of flowing osteophytes and right-sided thoracic predominance.

Gout must be differentiated from septic arthritis (gradual onset, systemic infection signs, single joint involvement), autoimmune arthritides (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), and reactive arthritis. Rheumatoid arthritis affects small joints symmetrically with morning stiffness. Ankylosing spondylitis causes inflammatory back pain and enthesitis. Reactive arthritis follows infections of the genitourinary, gastrointestinal, or skin. Patients with elevated uric acid but no inflammatory joint involvement do not have gout.

Psoriatic arthritis presents with HLA-B27 positivity, pencil-in-cup finger deformity, and negative RF; treated with NSAIDs/celecoxib first-line. Ankylosing spondylitis affects young males with HLA-B27 positivity (>90%), negative RF, and bamboo spine on X-ray; physical therapy is first-line, followed by NSAIDs. Distinguishing osteoarthritis (distal DIP/PIP involvement) from RA (PIP/MCP involvement) is critical. Septic arthritis requires synovial fluid aspiration showing >50,000 WBCs with neutrophil predominance; even with negative culture, vancomycin should be started for suspected S. aureus infection.

Gout typically affects the first metacarpophalangeal joint with asymmetric involvement, overhanging margins, and sclerotic borders. Psoriatic arthritis shows asymmetric distal interphalangeal joint involvement with pencil-in-cup deformity. Hemochromatosis arthropathy shows symmetric involvement of the second through fifth metacarpophalangeal joints with hook-like osteophytes. CPPD disease shows osteoarthritis-like changes with calcification of the triangular fibrocartilage complex. Ankylosing spondylitis shows syndesmophyte formation, sacroiliitis, and bamboo spine appearance.

Rheumatoid arthritis causes widespread systemic complications beyond joints. Pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6) released from inflamed joints enter systemic circulation, causing extra-articular manifestations. Skin involvement includes rheumatoid nodules from immune complex deposition. Liver produces elevated CRP and hepcidin, contributing to anemia of chronic disease. Cardiovascular involvement accelerates atherosclerosis, increasing myocardial infarction and stroke risk. Musculoskeletal complications include osteopenia progressing to osteoporosis, muscle weakness from insulin resistance, thrombocytosis from bone marrow involvement, and anemia. Neurological manifestations include fatigue and depression. Pulmonary involvement may include pleural effusion and lung infections, though some cases relate to treatment-related immunosuppression. These systemic effects demonstrate RA as a true systemic inflammatory disease.

Rheumatoid arthritis extends beyond joint involvement to affect multiple organ systems, with extra-articular manifestations occurring in approximately 40% of patients. General constitutional symptoms include fatigue, depression, malaise, weight loss, and cachexia. Organ-specific manifestations encompass cardiovascular complications (pericarditis, pericardial effusion, CHF, coronary artery disease), pulmonary involvement (pleural effusion, interstitial lung disease, chronic sialadenitis), ocular manifestations (keratoconjunctivitis sicca, episcleritis), neurological complications (carpal tunnel syndrome, peripheral neuropathy, radiculopathy, myelopathy), dermatological findings (rheumatoid nodules, Baker's cyst, pyoderma gangrenosum), and hematological abnormalities (anemia, neutropenia, lymphoma risk). Cervical spine involvement poses particular risk for cord compression and neurological deficits requiring urgent evaluation.

Rheumatoid arthritis is a systemic inflammatory disease that causes extra-articular manifestations affecting multiple organ systems, including cardiovascular (pericarditis, myocarditis, coronary artery disease), pulmonary (pleurisy, interstitial lung disease, pulmonary fibrosis), neurological (carpal tunnel syndrome, mononeuritis multiplex), ocular (keratoconjunctivitis sicca), and hematological (anemia, neutropenia, lymphoma) systems, with approximately 40% of RA patients experiencing these manifestations before or after arthritis onset.

Extra-articular manifestations occur in 30-40% of patients and correlate with rheumatoid factor and anti-CCP. Rheumatoid nodules appear on extensor surfaces. Ocular involvement includes secondary Sjögren's syndrome and episcleritis. Pulmonary manifestations include pleuritis with exudative effusion (low glucose, high protein, multinucleated giant cells), interstitial lung disease, and Caplan syndrome (pneumoconiosis with bilateral nodules). Cardiovascular involvement includes pericarditis and accelerated atherosclerosis. Neurological manifestations include peripheral neuropathy and cervical myelopathy from atlantoaxial subluxation. Felty's syndrome (arthritis, neutropenia, splenomegaly) and AA amyloidosis are rare complications.

Beyond joint involvement, RA affects multiple organ systems through two mechanisms: direct autoimmune attack on extrajoint synovial structures and systemic dissemination of immune complexes. Extra-articular manifestations include tenosynovitis/bursitis (affecting tendon sheaths), interstitial lung disease, pleural/pericardial effusions, subcutaneous nodules, episcleritis, and vasculitis. Type III hypersensitivity reactions occur when antigen-antibody complexes deposit in tissues, activating complement and recruiting neutrophils. Constitutional features (fever, weight loss, malaise) result from cytokines crossing the blood-brain barrier and altering hypothalamic function. Subcutaneous nodules are almost universally present in RF-positive patients. These systemic manifestations demonstrate RA's true multisystem nature beyond joint disease.